Novogen
Ltd. (Nasdaq: NVGN) announced that studies conducted by the University of
Queensland Diamantina Institute demonstrated that Ansina killed melanoma
cells irrespective of their mutational status. The stock price surged $1.01 to close at $5.52.
Studies support Novogen's Ansina
April 09, 2015 at 17:08 PM EDT
